<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585726</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT02585726</nct_id>
  </id_info>
  <brief_title>Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)</brief_title>
  <acronym>WAVES</acronym>
  <official_title>Lake Washington Vascular VenaSeal™ Post-Market Evaluation: WAVES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lake Washington Vascular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lake Washington Vascular</source>
  <brief_summary>
    <textblock>
      The VenaSeal Closure system offers an outpatient treatment option for the permanent closure
      of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through
      endovascular embolization with coaptation. VenaSeal is intended for use in adults with
      clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete closure (CC) of the PTVS as assessed by duplex ultrasound 1 month after the index procedure.</measure>
    <time_frame>1 month</time_frame>
    <description>CC of the PTVS as assessed by duplex ultrasound 1 month after the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CC of the PTVS, as assessed by duplex ultrasound</measure>
    <time_frame>1 week and 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC of Treated Vein Segments (TVS), expressed on a per-segment basis, as assessed by duplex ultrasound</measure>
    <time_frame>1 month and 3 months after the index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the venous clinical severity scores (rVCSS)</measure>
    <time_frame>1 and 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Aberdeen Varicose Vein Questionnaire (AVVQ)</measure>
    <time_frame>1 and 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the EQ-5D</measure>
    <time_frame>1 and 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to normal activities and return to work; day of procedure is day 0</measure>
    <time_frame>1 week, 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for adjunctive treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in case report form (yes or no, and if yes, the Investigator will specify what the adjunctive measure is).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse event for below the knee greater saphenous vein treatment</measure>
    <time_frame>1 week, 1 month, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse events for large diameter TVS defined as veins larger than 8 mm in diameter</measure>
    <time_frame>1 week, 1 month, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1 week, 1 month, 3 months</time_frame>
    <description>At selected visits, the subject will complete a brief questionnaire rating satisfaction with treatment provided and whether the subject would undergo the treatment again.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC of TVS, expressed on a per-segment basis</measure>
    <time_frame>1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Venous Reflux</condition>
  <arm_group>
    <arm_group_label>Historical Control with Propensity Analysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VenaSeal Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SP-402 VenaSeal™ Closure System</intervention_name>
    <description>A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..</description>
    <arm_group_label>Historical Control with Propensity Analysis</arm_group_label>
    <arm_group_label>VenaSeal Treatment Arm</arm_group_label>
    <other_name>VenaSeal™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Reflux in at least one target vein;

          -  One or more of the following symptoms related to a TV: aching, throbbing, heaviness,
             fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort,
             swelling;

          -  CEAP classification of C2 (if symptomatic) through C5;

        Key Exclusion Criteria:

          -  Current, regular use of systemic anticoagulation;

          -  Previous or suspected deep vein thrombosis or pulmonary embolus, or active acute
             superficial thrombophlebitis, or thrombophlebitis migrans;

          -  Previous treatment such as laser or radiofrequency ablation of venous disease in
             targeted vein segment;

          -  Known hypercoagulable disorder;

          -  Pregnant or breast feeding at enrollment;

          -  Known sensitivity to cyanoacrylate adhesives;

          -  Venous treatment in the contralateral limb within the last 30 days, or who require
             contralateral treatment within three months;

          -  Planned to undergo additional ipsilateral treatments on the same leg within 3 months
             following treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lake Washington Vascular, PLLC</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, Lohr JM, McLafferty RB, Meissner MH, Murad MH, Padberg FT, Pappas PJ, Passman MA, Raffetto JD, Vasquez MA, Wakefield TW; Society for Vascular Surgery; American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011 May;53(5 Suppl):2S-48S. doi: 10.1016/j.jvs.2011.01.079.</citation>
    <PMID>21536172</PMID>
  </reference>
  <reference>
    <citation>Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005 Mar;15(3):175-84. Review.</citation>
    <PMID>15723761</PMID>
  </reference>
  <reference>
    <citation>van den Bos R, Arends L, Kockaert M, Neumann M, Nijsten T. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg. 2009 Jan;49(1):230-9. doi: 10.1016/j.jvs.2008.06.030. Epub 2008 Aug 9. Review.</citation>
    <PMID>18692348</PMID>
  </reference>
  <reference>
    <citation>Geza M, Gloviczki P. Venous Embryology and Anatomy. In: Bergan JJ, editor. The Vein Book: Elsivier Academic Press; 2007.</citation>
  </reference>
  <reference>
    <citation>van Eekeren RR, Boersma D, de Vries JP, Zeebregts CJ, Reijnen MM. Update of endovenous treatment modalities for insufficient saphenous veins--a review of literature. Semin Vasc Surg. 2014 Jun;27(2):118-36. doi: 10.1053/j.semvascsurg.2015.02.002. Epub 2015 Feb 18. Review.</citation>
    <PMID>25868763</PMID>
  </reference>
  <reference>
    <citation>Guex JJ. Endovenous chemical (and physical) treatments for varices: what's new? Phlebology. 2014 May;29(1 suppl):45-48. Epub 2014 May 19. Review.</citation>
    <PMID>24843085</PMID>
  </reference>
  <reference>
    <citation>Davies HO, Popplewell M, Darvall K, Bate G, Bradbury AW. A review of randomised controlled trials comparing ultrasound-guided foam sclerotherapy with endothermal ablation for the treatment of great saphenous varicose veins. Phlebology. 2016 May;31(4):234-40. doi: 10.1177/0268355515595194. Epub 2015 Jul 9. Review.</citation>
    <PMID>26163507</PMID>
  </reference>
  <reference>
    <citation>El-Sheikha J, Carradice D, Nandhra S, Leung C, Smith GE, Campbell B, Chetter IC. Systematic review of compression following treatment for varicose veins. Br J Surg. 2015 Jun;102(7):719-25. doi: 10.1002/bjs.9788. Epub 2015 Apr 2. Review.</citation>
    <PMID>25833417</PMID>
  </reference>
  <reference>
    <citation>Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011 Aug;98(8):1079-87. doi: 10.1002/bjs.7555.</citation>
    <PMID>21725957</PMID>
  </reference>
  <reference>
    <citation>Bootun R, Lane TR, Davies AH. The advent of non-thermal, non-tumescent techniques for treatment of varicose veins. Phlebology. 2016 Feb;31(1):5-14. doi: 10.1177/0268355515593186. Epub 2015 Jun 30. Review.</citation>
    <PMID>26130051</PMID>
  </reference>
  <reference>
    <citation>Morrison N, Gibson K, McEnroe S, Goldman M, King T, Weiss R, Cher D, Jones A. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015 Apr;61(4):985-94. doi: 10.1016/j.jvs.2014.11.071. Epub 2015 Jan 31.</citation>
    <PMID>25650040</PMID>
  </reference>
  <reference>
    <citation>Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology. 2015 Jul;30(6):397-404. doi: 10.1177/0268355514532455. Epub 2014 Apr 30.</citation>
    <PMID>24789750</PMID>
  </reference>
  <reference>
    <citation>Proebstle TM, Alm J, Dimitri S, Rasmussen L, Whiteley M, Lawson J, Cher D, Davies A. The European multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):2-7. doi: 10.1016/j.jvsv.2014.09.001. Epub 2014 Oct 18.</citation>
    <PMID>26993674</PMID>
  </reference>
  <reference>
    <citation>Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, Meissner MH, Rutherford RB; American Venous Forum Ad Hoc Outcomes Working Group. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010 Nov;52(5):1387-96. doi: 10.1016/j.jvs.2010.06.161. Epub 2010 Sep 27.</citation>
    <PMID>20875713</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicose Veins</keyword>
  <keyword>Great Saphenous Vein</keyword>
  <keyword>Venous Insufficiency</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

